Dexamethasone sodium phosphate injection

A technology of dexamethasone sodium phosphate and injection, which is applied in drug delivery, organic active ingredients, antipyretics, etc., can solve the problems of large cumulative amount and potential harm to human body, and reduce production costs, save production costs, Ensure safe and effective medication

Active Publication Date: 2008-02-13
TIANJIN PHARMA GROUP XINZHENG
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] In the production process of dexamethasone sodium phosphate injection, the concentration generally adopted by manufacturers is about 30% (volume ratio; that is, 3000ml of medicinal propylene glycol needs to be added for every 10,000ml of dexamethasone sodium phosphate liquid medicine prep...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Embodiment 1, dexamethasone sodium phosphate injection, is made up of the phosphate buffer saline, dexamethasone sodium phosphate and injection water of the medicinal propylene glycol of 4% by volume ratio, 0.3% PH8.0, dexamethasone sodium phosphate content 2mg per ml injection.

Embodiment 2

[0021] Embodiment 2. In this embodiment, the content of dexamethasone sodium phosphate is 5 mg per ml of injection, and the others are the same as in Embodiment 1.

Embodiment 3

[0022] Embodiment 3, dexamethasone sodium phosphate injection, is made up of the phosphate buffer saline, dexamethasone sodium phosphate and water for injection of the medicinal propylene glycol of 5% by volume ratio, 0.4% PH8.0, dexamethasone sodium phosphate content 2mg per ml injection.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Dexamethasone sodium phosphate injection comprises the medicinal propanediol with the volume ratio of 4 percent to 6 percent, the phosphate buffer of 0.3 percent to 0.5 percent with the PH value of 8.0, the dexamethasone sodium phosphate and the injection water. Content of the dexamethasone sodium phosphate is 2mg to 5 mg per ml. The application is safe and the cost is low in the present invention.

Description

technical field [0001] The invention belongs to the technical field of medical preparations, in particular to a dexamethasone sodium phosphate injection. Background technique [0002] Dexamethasone sodium phosphate, chemical name 16α-methyl-11β,17α,21-trihydroxy-9α-flupregna-1,4-diene-3,20-dione-21-phosphate disodium salt , is an adrenal cortex hormone drug with anti-inflammatory, anti-allergic, anti-rheumatic, and immunosuppressive effects. The mechanism of action is: (1) Anti-inflammatory effect: it can reduce and prevent the response of tissues to inflammation, thereby reducing the manifestation of inflammation. It can inhibit the accumulation of inflammatory cells, including macrophages and leukocytes, at the site of inflammation, and inhibit phagocytosis, the release of lysosomal enzymes, and the synthesis and release of inflammatory chemical mediators. (2) Immunosuppressive effects: including preventing or inhibiting cell-mediated immune responses, delayed allergic r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/08A61K31/573A61P29/00A61P37/06A61P37/08
Inventor 周遂成陈智锋
Owner TIANJIN PHARMA GROUP XINZHENG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products